List of Excipients in Branded Drug GUAIFENESIN EXTENDED-RELEASE 600 MG

« Back to Dashboard

Generic Drugs Containing GUAIFENESIN EXTENDED-RELEASE 600 MG

Company	Ingredient	NDC	Excipient
Guardian Drug Company	guaifenesin	53041-233	CARBOMER HOMOPOLYMER TYPE B
Guardian Drug Company	guaifenesin	53041-233	CELLULOSE, MICROCRYSTALLINE
Guardian Drug Company	guaifenesin	53041-233	HYPROMELLOSE 2208
Guardian Drug Company	guaifenesin	53041-233	POVIDONE

What are the Most Frequently-Used Excipients in GUAIFENESIN EXTENDED-RELEASE 600 MG?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE B
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE 2208
1	POVIDONE

Guaifenesin Extended-Release 600 mg: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 17, 2026

Guaifenesin extended-release 600 mg is a mature OTC dosage form with broad generic availability, established consumer demand, and limited dependence on active-ingredient differentiation. The main commercial opportunities are lower-cost private-label products, improved swallowability, cleaner excipient profiles, tamper-resistant packaging, and combination products containing dextromethorphan. The strongest technical position is usually created through reliable 12-hour release, tablet robustness, dissolution control, and manufacturing efficiency rather than through guaifenesin itself.

What is guaifenesin extended-release 600 mg?

Guaifenesin is an expectorant used to loosen phlegm and thin bronchial secretions. A 600 mg extended-release tablet is generally labeled for adults and children 12 years and older, with dosing commonly set at one or two tablets every 12 hours, subject to the applicable product labeling.[1][2]

The product is designed to provide twice-daily dosing instead of the more frequent dosing associated with immediate-release guaifenesin. The dosage form is normally a matrix tablet that controls water penetration, drug diffusion, and matrix erosion.

Product attribute	Typical commercial profile
Active ingredient	Guaifenesin
Strength	600 mg per tablet
Dosage form	Extended-release tablet
Primary route	Oral
Main indication	Expectorant
Typical dosing interval	Every 12 hours
Primary market	U.S. OTC
Reference brand	Mucinex 600 mg Extended-Release Tablets
Main competitors	Store-brand and generic guaifenesin ER products
Common combination	Guaifenesin 600 mg plus dextromethorphan 30 mg

Guaifenesin has high dose loading relative to many oral solid drugs. That creates a practical formulation problem: the tablet must contain 600 mg of active ingredient while retaining adequate mechanical strength, acceptable dimensions, controlled release, and reliable packaging performance.

What excipient strategy is used for guaifenesin ER 600 mg?

The preferred formulation platform is a hydrophilic matrix containing a swellable polymer, a compression aid, a disintegrant or pore-forming component, a lubricant, and a film coat. The formulation must control drug release without creating an oversized tablet or excessive tablet hardness.

Hydrophilic matrix polymers

Hypromellose is the most commercially established matrix polymer for this type of product. It hydrates after ingestion and forms a gel layer around the tablet. The gel controls water penetration and slows guaifenesin diffusion.

Polymer selection should consider:

• Viscosity grade
• Polymer concentration
• Particle size
• Substitution pattern
• Hydration rate
• Sensitivity to compression force
• Impact on dissolution after storage

Higher-viscosity hypromellose can reduce early release but may increase tablet size, compression sensitivity, and process variability. Lower-viscosity grades can improve manufacturability but may require higher concentrations or a secondary release-control mechanism.

Compression and bulk-density excipients

Microcrystalline cellulose is commonly used to improve compactibility and tablet strength. It can also improve powder flow when the guaifenesin particle-size distribution is controlled.

Lactose, dibasic calcium phosphate, mannitol, and starch-based fillers are possible alternatives. Each creates different technical and commercial tradeoffs:

Excipient class	Commercial benefit	Main risk
Microcrystalline cellulose	Strong compacts and broad supplier availability	Can increase tablet bulk
Lactose	Low cost and established supply	Moisture and compatibility considerations
Dibasic calcium phosphate	High density and good flow	Brittle compacts and potential dissolution effects
Mannitol	Consumer-friendly mouthfeel	Higher cost and possible compression limitations
Pregelatinized starch	Binding and processing support	May alter hydration and release

Because guaifenesin is present at a high weight percentage, the formulation cannot rely on the excipient system to compensate for poor active-material flow. Particle engineering, granulation, and controlled blending are often as important as the excipient selection.

Disintegrants and pore-forming agents

A conventional immediate-release disintegrant can be used at a controlled level to prevent excessive release retardation. Sodium starch glycolate, croscarmellose sodium, and crospovidone are potential options.

The formulation objective is not rapid tablet breakup. It is controlled creation of water channels within the matrix. Excessive disintegrant can generate dose dumping or an overly rapid initial release. Insufficient disintegrant can produce slow, incomplete, or batch-variable release.

Binders and granulation aids

Povidone, copovidone, hypromellose, and starch binders can improve granule strength and reduce segregation. Wet granulation may be useful when guaifenesin flow or compressibility is inadequate. Direct compression may reduce manufacturing cost but requires tighter control of particle size, bulk density, and lubricant distribution.

A high-dose guaifenesin tablet is a strong candidate for a formulation-development comparison between:

1. Direct compression with engineered guaifenesin.
2. Dry granulation by roller compaction.
3. Wet granulation using an aqueous binder system.

The selected process should be judged by dissolution reproducibility, tablet friability, compression speed, yield, and scale-up behavior.

Lubricants and glidants

Magnesium stearate is widely used, but over-lubrication can reduce tablet tensile strength and slow wetting. The formulation should establish a narrow blending-time range because lubricant exposure can affect both mechanical properties and drug release.

Colloidal silicon dioxide can improve flow and reduce sticking. Its level should be balanced against dusting, segregation, and blend uniformity.

Film coating

A film coat can improve appearance, swallowability, identification, abrasion resistance, and moisture protection. Immediate-release film coatings are usually preferable when the release mechanism is based on the tablet core.

The coating should not unintentionally create a second rate-controlling barrier unless the product is specifically designed as a membrane-controlled system. A thin, low-moisture coating can support packaging and consumer acceptance without materially changing dissolution.

What dissolution profile should guaifenesin ER 600 mg achieve?

The key performance requirement is controlled release over approximately 12 hours with no clinically meaningful dose dumping. Product-specific dissolution criteria are established in the approved application or supporting regulatory file, while the OTC monograph provides the relevant active-ingredient and labeling framework.[1][3]

A development program should assess:

• Early release during the first hour
• Intermediate release at approximately four to eight hours
• Near-complete release by the end of the target interval
• Agitation sensitivity
• Media pH sensitivity
• Alcohol sensitivity where relevant
• Effect of tablet splitting or crushing
• Release after accelerated and long-term storage

Alcohol dose-dumping studies are particularly relevant for modified-release oral products. A formulation that meets dissolution in standard aqueous media but releases guaifenesin rapidly in hydroalcoholic conditions creates a regulatory and product-liability risk.

A robust formulation should also withstand normal consumer handling. Labeling commonly instructs users to swallow extended-release tablets whole rather than crush, chew, or break them.[2]

What FDA regulatory pathway applies to guaifenesin ER 600 mg?

Guaifenesin is covered by the FDA OTC monograph framework for expectorant products. The relevant federal requirements include the active ingredient, dosage, indications, warnings, and labeling provisions in 21 C.F.R. Part 341.[1]

A product that conforms to the applicable OTC monograph can generally be marketed without the same premarket approval pathway used for a new prescription drug. A formulation or labeling approach outside the monograph may require an FDA application or another regulatory basis.

FDA status and Orange Book position

Mucinex and comparable guaifenesin ER 600 mg products are OTC consumer products. The Orange Book is principally a listing for approved prescription and certain approved drug products, including related patent and exclusivity information. OTC monograph products do not generally create the same Orange Book patent-certification framework as approved prescription medicines.[3][4]

This distinction affects generic-entry analysis:

• Paragraph IV litigation is usually not the central entry mechanism.
• ANDA litigation is less relevant where the product is marketed under the OTC monograph system.
• Market entry is driven more by monograph compliance, labeling, quality, manufacturing, trademarks, and retail distribution.
• Brand owners may still enforce formulation, process, packaging, trademark, or other intellectual-property rights outside the Orange Book framework.

What patents protect guaifenesin extended-release 600 mg?

The active ingredient itself is long-established and does not provide a meaningful composition-of-matter barrier. The commercial patent value, where it exists, is more likely to reside in the formulation, release-control architecture, manufacturing process, coating, combination product, or packaging.

Potential claim categories include:

Claim category	Potential subject matter	Commercial impact
Matrix formulation	Polymer type, concentration, and release profile	May constrain close formulation copies
Manufacturing process	Granulation, compression, coating, or curing conditions	Usually difficult to detect from the finished product
Combination product	Guaifenesin plus dextromethorphan or another active	More relevant for branded combination products
Dosage regimen	Twice-daily expectorant use	Often limited by OTC monograph and prior art
Packaging	Child-resistant, unit-dose, or moisture-control system	Usually supports product differentiation
Trademark and trade dress	Mucinex branding and product presentation	Often more commercially important than patent rights

How strong is the patent estate for guaifenesin ER 600 mg?

The patent estate is generally weaker than the estate surrounding a new prescription drug or biologic. The main reasons are:

1. Guaifenesin is an old active ingredient.
2. Extended-release oral matrices are a mature technology.
3. Numerous polymers and excipient combinations are available.
4. A competitor can often design around a narrowly drafted formulation claim.
5. OTC monograph status reduces dependence on Orange Book exclusivity.

A formulation patent can still have value if it claims a specific release profile, manufacturing parameter, or combination that is difficult to reproduce economically. The practical strength depends on claim breadth, prosecution history, prior-art disclosures, enforcement cost, and whether the finished dosage form can reveal infringement.

When does guaifenesin ER 600 mg lose exclusivity?

There is no single prescription-style loss-of-exclusivity date for guaifenesin ER 600 mg. The active ingredient is long off-patent, and multiple OTC products already compete in the category.

The commercial exclusivity structure is divided among:

• Active-ingredient freedom to operate
• Formulation patents, if enforceable
• Brand trademarks
• Retail distribution agreements
• Consumer recognition
• Manufacturing know-how
• Regulatory compliance
• Packaging and product presentation

For a new entrant, the principal barrier is not waiting for a patent expiration date. It is achieving a compliant, stable, cost-effective product and securing retail or e-commerce placement.

Are there Paragraph IV challenges for guaifenesin ER 600 mg?

Paragraph IV challenges are not normally the primary pathway for competing monograph-compliant OTC guaifenesin products. Paragraph IV certifications relate to patents listed for approved drug products in the Orange Book under the Hatch-Waxman framework.[4]

A competitor seeking to market a guaifenesin ER 600 mg product generally focuses on:

• Conformance with 21 C.F.R. Part 341
• Appropriate labeling
• Drug establishment registration
• Current good manufacturing practice compliance
• Product quality and stability
• Trademark clearance
• Patent and trade-secret freedom-to-operate review

A branded OTC product with an NDA or other approved application could present a different patent and exclusivity profile. That analysis must be performed product by product.

What generic and private-label launch opportunities exist?

The strongest commercial opportunity is a low-cost, retailer-specific or e-commerce product that matches the established consumer proposition: 600 mg, 12-hour relief, single active ingredient, and familiar tablet presentation.

Single-ingredient guaifenesin ER

Single-ingredient products have the simplest regulatory and manufacturing profile. Opportunities include:

• Retailer private labels
• Club-store multipacks
• Value bottles with 40, 60, or more tablets
• Smaller trial packages
• Pharmacy-counter and online distribution
• Sugar-free and allergen-positioned formulations where supported by labeling

The category is price-sensitive. Cost advantages are most likely to come from high-speed compression, efficient coating, large-scale packaging, and procurement of guaifenesin and matrix polymers.

Guaifenesin and dextromethorphan combinations

Guaifenesin 600 mg combined with dextromethorphan 30 mg creates a larger commercial opportunity but introduces greater technical and regulatory complexity. The product must control two actives with different dose, solubility, and release requirements.

Key development risks include:

• Dextromethorphan release occurring too quickly
• Drug-drug or excipient interactions
• Larger tablet size
• More complicated labeling
• Increased warning requirements
• Higher risk of medication errors
• More complex dissolution specifications

Combination products can command higher retail prices, but they face stronger brand competition and a greater need for differentiated consumer positioning.

Improved swallowability and tablet design

A large 600 mg active dose can create tablet-size and swallowability problems. Commercially useful approaches include:

• Oval or capsule-shaped tablets
• Low-friction film coatings
• Tablet-edge optimization
• Reduced tablet thickness
• Smooth surface finish
• High-strength cores that resist chipping
• Packaging that minimizes abrasion during distribution

Any change to tablet shape must preserve release performance and avoid creating a misleading similarity to another branded product.

What manufacturing and IP barriers affect market entry?

Manufacturing barriers are moderate rather than extreme. The product does not require sterile production, biologic processing, complex delivery devices, or high-containment facilities. The principal technical barriers are process control and cost.

Manufacturing risks

Important risks include:

• Guaifenesin segregation during blending
• Poor powder flow
• Sticking and picking during compression
• Lubricant overexposure
• Tablet capping or lamination
• Coating defects
• Variable matrix hydration
• Dissolution drift during scale-up
• Moisture-related stability changes
• Packaging abrasion

Intellectual-property risks

The relevant freedom-to-operate review should cover:

• U.S. and foreign formulation patents
• Expired and abandoned patent families
• Continuation applications
• Combination-product claims
• Manufacturing-process patents
• Coating and packaging claims
• Trademarks and trade dress
• Trade secrets relating to granulation and compression

Because process patents may not be visible from the finished tablet, a manufacturer should maintain records showing independent development, supplier controls, process parameters, and nonuse of confidential third-party information.

How does guaifenesin ER 600 mg compare with immediate-release guaifenesin?

Attribute	Extended-release 600 mg	Immediate-release guaifenesin
Dosing	Commonly every 12 hours	More frequent dosing
Tablet complexity	Higher	Lower
Excipient dependence	Strong matrix-control requirement	Primarily compression and disintegration
Manufacturing cost	Higher	Lower
Consumer convenience	Better	Lower
Dissolution risk	Higher	Lower
Patent differentiation	More possible through formulation	Limited
Regulatory complexity	Greater due to modified release	Simpler

The extended-release product has a stronger consumer convenience proposition. The immediate-release product has a lower technical barrier and may compete effectively on price, especially where consumers prioritize cost over dosing frequency.

What is the commercial outlook for guaifenesin ER 600 mg?

The market is mature, but it remains commercially useful because cough, cold, and chest-congestion products have recurring seasonal demand. Brand revenue is exposed to generic substitution, retailer private labels, promotional pricing, and shifts toward combination products.

The strongest opportunities are:

1. High-volume private-label supply.
2. Cost-optimized single-ingredient tablets.
3. Combination products with differentiated packaging.
4. E-commerce multipacks.
5. Better swallowing and lower-abrasion tablets.
6. Products positioned around simpler excipient profiles.
7. Contract manufacturing for pharmacy and retail chains.

The weakest opportunity is a premium-priced copy with no measurable advantage in release performance, tablet usability, packaging, or consumer trust.

Key Takeaways

• Guaifenesin ER 600 mg is a mature OTC product with broad competition.
• The core formulation is typically a hydrophilic matrix tablet using hypromellose or a comparable release-control polymer.
• Excipient selection must balance 12-hour release, high drug loading, tablet strength, manufacturability, and swallowability.
• The active ingredient provides little meaningful exclusivity protection.
• Formulation, process, packaging, trademark, and trade-dress rights are more commercially relevant than Orange Book exclusivity.
• Paragraph IV litigation is generally not the principal competitive-entry mechanism for monograph-compliant OTC products.
• The best commercial opportunities are private-label supply, efficient manufacturing, combination products, and improved tablet usability.
• A successful launch depends more on dissolution consistency, cost, quality, and distribution than on a novel excipient system.

FAQs

Can guaifenesin ER 600 mg be formulated by direct compression?

Yes. Direct compression can reduce process steps and manufacturing cost, but the active ingredient must have adequate flow, compressibility, and particle-size control. Roller compaction or wet granulation may provide better uniformity when direct compression produces segregation or weak tablets.

Is hypromellose required for guaifenesin extended release?

No. Hypromellose is a common matrix polymer, but other hydrophilic polymers, wax-based systems, or coated multiparticulate approaches may be suitable. The selected system must meet product-specific dissolution and stability requirements.

Can a guaifenesin ER 600 mg tablet be scored?

A score line can create dose-splitting and release-control issues. The tablet should not be marketed as divisible unless the product has been specifically designed, tested, and labeled for splitting.

What is the main regulatory risk for a new OTC guaifenesin ER product?

The main risks are nonconforming labeling, failure to meet modified-release dissolution requirements, inadequate stability, manufacturing deviations, and failure to comply with current good manufacturing practice requirements.

Does a cleaner excipient label create a strong commercial advantage?

Usually, not by itself. A simpler excipient profile can support retailer requirements or targeted consumer positioning, but it must be paired with a tangible benefit such as improved swallowability, reduced tablet size, better tolerability, or a clear allergen-related claim supported by the finished product.

References

1. Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. U.S. Government Publishing Office.

2. DailyMed. (n.d.). Mucinex extended-release tablets, guaifenesin 600 mg: Drug facts and inactive ingredients. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). OTC monograph drugs and the nonprescription drug regulatory framework. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.